Novo Nordisk's Week: EU Nod for Haemophilia Drug, FDA Queries on Eye Risk, and a Wider 2026 Outlook
Published on 11/14/2026 at 11:01 | Editorial boerse-global.de
Novo Nordisk opened a busy stretch with a fresh European approval and a raised full-year forecast already in hand, while US regulators pressed the company on a different front entirely. The Danish drugmaker said the European Commission cleared FREHEMGO, its haemophilia A therapy, and confirmed it will roll out 26 scientific presentations at ObesityWeek in Washington, D.C., a conference running through 17 November.
The EU green light covers FREHEMGO, whose active ingredient is denecimig, for routine bleeding prophylaxis in adults and children with haemophilia A. The approval spans patients both with and without inhibitors, giving Novo a shot at several distinct groups — provided pricing talks and reimbursement decisions open the door. Novo intends to launch in the first European countries next year, and that rollout, rather than the approval itself, is what will determine how quickly the product earns its keep.
Trial Data Make the Case; Reimbursement Decides the Revenue
The clinical package behind the filing looks strong. In the FRONTIER2 study, patients previously treated on demand saw treated bleeds fall by 98.7% with monthly dosing compared with continued on-demand therapy, and weekly dosing also delivered a significant improvement in that group. Among 196 patients already on factor prophylaxis, annual bleeding rates dropped 54.0% on a weekly schedule and 42.8% on a monthly one. Results in younger children matched those in older patients, and FRONTIER5, which tracked patients switching directly from emicizumab, turned up no new safety signals.
FREHEMGO is injected under the skin through a single-use prefilled pen, with approved dosing intervals stretching from weekly to monthly — a range that could suit different patient needs if it holds up in everyday care. What stands between the approval and actual revenue is country-by-country negotiation over price and coverage. Named launch markets and confirmed access terms would sharpen the picture; until then, the sales potential rests largely on execution.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A Factory Snag Clouds the US Timeline
The bigger risk sits on the American side. According to Reuters, the FDA extended its review of FREHEMGO in October because of ongoing work at a manufacturing site. Novo said no clinical deficiencies were identified, leaving progress on production requirements as the pivotal variable for the US launch, which the company is targeting for the first half of 2027. Further delays at the plant or in the regulatory review could push back the US contribution, and an existing approval in Saudi Arabia says little about how the American process will end.
Separately, Reuters reported that the FDA asked Novo on Monday for additional product information on a possible link to rare, serious vision loss. The request covers Ozempic and Wegovy, among other products, and extends to comparable medicines from Eli Lilly.
Liver Analysis and a Higher Guidance Band
On the obesity side, Novo disclosed on 8 November a post-hoc analysis of the ESSENCE study of Wegovy in adults with the liver disease MASH, liver scarring and a body mass index below 27 kg/m². After 72 weeks, treatment was associated with improvements across several liver markers, including measures of liver damage, disease activity and fibrosis. Novo explicitly labelled the analysis exploratory and hypothesis-generating — an observed association, not a confirmed causal treatment effect for this patient group.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Financially, the company lifted its 2026 outlook on 4 November alongside third-quarter results. Adjusted revenue growth is now expected at constant exchange rates in a range of -2% to +2%, and the same band applies to adjusted operating profit growth. Novo had previously guided to declines of 0% to 6% on both measures, so the new forecast leaves room for either contraction or expansion over the full year.
The stock rose 2.7% yesterday, though no link to the announced presentations can be drawn from that move.
Ad
Novo Nordisk Stock: New Analysis - 14 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
